Statement Pursuant to Listing Rule 4.7C.3
November 5, 2020
Imagion Biosystems advises that in accordance with Listing Rule 4.7C.3, and as noted in the Item 6 of the Appendix 4C Cashflow Statement lodged by
Category: Investor updates
Quarterly Activity Report and Appendix C
October 26, 2020
Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after costs) in
Appendix 3Y — Change of Director’s Interest Notice
October 21, 2020
Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Appendix 2A — Fully Paid Ordinary Shares
October 21, 2020
Imagion Biosystems has submitted “Appendix 2A — Application for quotation of +securities.” Read Appendix 2A.
Vesting of Performance Rights
October 21, 2020
Imagion Biosystems has advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO Bob Proulx today, Thursday
Notice Pursuant to Section 708(5)(e) of the Corporations Act 2001
October 19, 2020
Imagion Biosystems gives notice that, on 20 October 2020 the Company issued 2,401,900 fully paid ordinary shares (Shares) in the Company as the result of
IBX Secures Additional Capital — Shareholders Exercise Options
October 19, 2020
Imagion Biosystems announced that it has received a total of $143,157 for the exercise of options. Composed of $142,200 for 2,370,000 options exercisable at 6
Imagion Biosystems Appoints Geoff Hollis as CFO
October 19, 2020
Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the Company moves into its
HREC Approval for Phase I Study
October 8, 2020
Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense® HER2 Phase I study
Issue of Unlisted Performance Options under EIP
October 5, 2020
Imagion Biosystems today announced “Issue of unlisted performance options under Equity Incentive Plan”. Read the announcement.